Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
|
This article is part of Pulmonology Advisor‘s coverage of the ACAAI 2019 meeting, taking place in Houston, TX. Our staff will report on medical research related to allergies, asthma, and more conducted by experts in the field. Check back regularly for more news from ACAAI 2019. |
HOUSTON — Dupilumab has demonstrated consistency in effective asthma control across baseline levels of immunoglobulin E (IgE) among individuals with uncontrolled, moderate to severe asthma with high baseline eosinophils. This research was presented at the 2019 American College of Allergy, Asthma, & Immunology Annual Scientific Meeting, held November 7 to 11, 2019, in Houston, Texas.
Researchers conducted a post-hoc analysis of the phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov Identifier: NCT02414854) to determine the effect of dupilumab on asthma control among individuals with elevated baseline eosinophils (≥150 cells/µL) using measurements of baseline IgE levels (categorized as <100, 100 to <500, or ≥500 IU/mL). Participants were given dupilumab 200/300 mg every 2 weeks or placebo.
The Asthma Control Questionnaire-5 (ACQ-5) was used to assess asthma control, in which scores of 0 to 6 corresponded with totally controlled to severely uncontrolled, respectively. The threshold for clinically meaningful change was ≥0.5 change in ACQ-5 score. At weeks 24 and 52, a mixed effects model with repeated measures was used to assess changes from baseline.
Dupilumab 200/300 mg was associated with significant reduction in ACQ-5 scores at weeks 24 (least squares mean difference [LSMD], -0.53 to -0.28; P <.05) and 52 (LSMD, -0.57 to -0.35; P <.05) compared with placebo, with the exception of dupilumab 300 mg at week 24 (<100 IgE level group: LSMD, -0.24; P =.11; ≥500 IU/mL IgE level group: LSMD, -0.22; P =.19) and at week 52 (≥500 IU/mL IgE level group: LSMD, 0.09; P =.57). Injection site reaction was the most common adverse event among both the dupilumab (15%/18%) and placebo (5%/10%) groups.
The study researchers concluded that, among individuals with “uncontrolled, moderate to severe asthma with elevated baseline eosinophils,” dupilumab demonstrated an “overall consistent [effect] across baseline IgE levels.”
|
Visit Pulmonology Advisor‘s conference section for continuous coverage from ACAAI 2019. |
Reference
Carr W, Corren J, Rice M, et al. Dupilumab improved asthma control across baseline immunoglobulin E levels: Liberty Asthma Quest Study. Presented at: American College of Allergy, Asthma, & Immunology Annual Scientific Meeting 2019; November 7-11, 2019; Houston, TX. Abstract P223.
